"Phenoxodiol demonstrates an ability in prostate cancer cells to induce significant cytotoxicity in cells by interacting with p21(WAF1) and inducing cell cycle arrest irrespective of p53 status or caspase pathway interactions. These data indicate that phenoxodiol would be effective as a potential future treatment modality for both hormone sensitive and hormone refractory prostate cancer."
Yes, they are the same. It is also called dehydroequol. But a chemical isn't all there is to a drug. Its formulation may be critical to its efficacy because of the way it's metabolized.
There was a clinical trial of idronoxil for prostate cancer 10 years ago. It had no activity and results were not published.
Graham Kelley was the lead investigator. He wrote the following for Noxopharm investors in 2016, updated last year. He explains why he thinks it did not work in earlier clinical trials, and why he thinks that the Veyonda reformulation might work where idronoxil failed in the past:
The Phase 2 trial on 16 men paired Veyonda with Lu-177-PSMA therapy. It very well may be that Veyonda overcomes radioresistance in cancer cells while not increasing radiotoxicity in healthy cells. Both conditions have to be met in any radioadjuvant therapy. It will also be interesting to see if it improves response to chemo without increasing its toxicity. Not to be a downer, but it is important to remember that several kinase inhibitors (e.g., cabozantanib, imatinib, etc.) showed promise in Phase 2 trials but failed in Phase 3.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Anti-proliferative effect of Cannabidiol in Prostate cancer cell PC3
Today, received first infusion of Taxotere, while PSA <0.02...
Nitric-Oxide-Donating NSAIDs.
